Structure Therapeutics Inc. SEC filings document a Cayman Islands clinical-stage biopharmaceutical issuer whose Nasdaq-listed American depositary shares each represent three ordinary shares. The filings identify the company’s ADS and ordinary-share structure, Exchange Act reporting status, material agreements, and formal corporate-governance matters.
Recent 8-K reports cover financial results and corporate updates, Regulation FD disclosures for aleniglipron clinical data, amendments to a sales agreement, executive appointment and compensation matters, and shareholder-vote results. Proxy materials describe annual general meeting proposals, director elections, auditor ratification, advisory executive-compensation votes, board governance, and related shareholder procedures.
Structure Therapeutics chief scientific officer Xichen Lin exercised options for 11,817 Ordinary Shares at $0.34 per share on August 4, 2026, converted them into 3,939 American Depositary Shares, and sold all ADS in two trades at weighted average prices of $49.2857 and $50.0290 pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026. Following this partial exercise, a share option over 154,715 Ordinary Shares remains outstanding.
FMR LLC, a more than 10% owner of Structure Therapeutics Inc., reported indirect sales totaling 17,452 American Depositary Shares on July 22, 2026, in open-market or private transactions at a weighted average $50.07 per ADS via F-Prime funds. Each ADS represents three ordinary shares. FMR and related persons continue to report large indirect holdings, including positions tied to 4,546,674 ordinary shares, and disclaim beneficial ownership of the reported securities.
Structure Therapeutics Inc. chief scientific officer Xichen Lin exercised share options covering 23,634 Ordinary Shares at $0.34 per share, converted them into 7,878 American Depositary Shares, and sold all 7,878 ADS at weighted average prices of $50.7956 and $51.7088 per ADS under a Rule 10b5-1 trading plan entered into on March 26, 2026. Following these transactions, Lin holds 228,960 Ordinary Shares directly and options over 166,532 Ordinary Shares exercisable at $0.34 per share until September 10, 2029.
Structure Therapeutics Inc.’s Chief Scientific Officer, Xichen Lin, reported an exercise-and-sale transaction involving American Depositary Shares (ADS) tied to the company’s Ordinary Shares.
Lin exercised share options for 23,634 Ordinary Shares at $0.34 per share, which were converted into 7,878 ADS and then sold at $49.0792 per ADS under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Lin holds 228,960 Ordinary Shares directly and retains share options covering 190,166 additional Ordinary Shares.
Structure Therapeutics Inc. director Russell Angus C. received a grant of options covering 39,453 Ordinary Shares at an exercise price of $15.00 per share. The options vest in equal monthly installments over 12 months after June 17, 2026 and will be fully vested before the 2027 annual shareholder meeting. Following this award, he holds 39,453 derivative securities, which expire on June 16, 2036.
Structure Therapeutics Inc. director Ted W. Love received a grant of share options, giving him the right to buy 39,453 Ordinary Shares. The options have an exercise price of $15.00 per share, set at the fair market value on the grant date.
The options vest in equal monthly installments over the 12 months following June 17, 2026 and will be fully vested immediately before the company’s 2027 annual shareholder meeting. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. director Joanne Waldstreicher received a grant of options to buy 39,453 Ordinary Shares at an exercise price of $15.00 per share. The options vest in equal monthly installments over 12 months following June 17, 2026 and will be fully vested before the company’s 2027 annual shareholder meeting. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics director Eric Dobmeier received a new stock option grant covering 39,453 Ordinary Shares. The option has an exercise price of $15.00 per share, set at the fair market value on the grant date based on the trading price of the company’s American Depositary Shares (ADSs).
The option vests in equal monthly installments over the 12 months following June 17, 2026, and will be fully vested no later than immediately before the company’s 2027 annual shareholder meeting. The option expires on June 16, 2036. Each ADS represents three Ordinary Shares. Following this grant, Dobmeier holds 39,453 options directly.
Structure Therapeutics Inc. director Sharon Tetlow received a grant of options covering 39,453 Ordinary Shares. The options have an exercise price of $15.00 per share and expire on June 16, 2036. These options vest in equal monthly installments over the 12 months following June 17, 2026, and will be fully vested immediately before the company’s 2027 annual shareholder meeting. Each American Depositary Share represents three Ordinary Shares.